Letter by Damen et al Regarding Article, “A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the critical appraisal by Gargiulo et al, 1 who are to be commended for their comprehensive article on the history and subsequent developments in the secondary prevention of coronary artery disease with antiplatelet therapy.
We agree with the authors that single P2Y12 inhibition or shorter duration of dual antiplatelet therapy should more often be considered. Especially in patients at low-risk of thrombotic events, prolonged dual antiplatelet therapy duration beyond 1 year came at the …